NCT05208814View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and Safety of TPN171H Tablets in Patients with Renal Insufficiency and Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

October 25, 2022

Study Completion Date

October 25, 2022

Conditions
Pulmonary Arterial HypertensionErectile Dysfunction
Interventions
DRUG

TPN171H single dose

10 mg TPN171H taken once

Trial Locations (2)

610041

West China Hospital, Chengdu

610055

Chengdu Xinhua Hospital, Chengdu

All Listed Sponsors
collaborator

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

OTHER

lead

Vigonvita Life Sciences

INDUSTRY